

## PBLD - Table # 24

A three week old neonate with hemochromatosis presenting for liver transplantation.

### **Moderators and Institutions:**

Lianne L. Stephenson, M.D., Department of Anesthesiology, University of Wisconsin Hospital and Clinics, Madison, WI

Christian Seefelder, M.D., Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, MA

### **Objectives:**

Understand the differences in indications for liver transplantation between neonates and other age groups.

Understand the implications of hemochromatosis.

Understand the ranking on the pediatric transplant waiting list.

Understand surgical techniques used in pediatric liver transplantation.

Understand the specific neonatal issues for anesthesia for liver transplantation in neonates.

### **Case History:**

A neonate develops signs of liver failure soon after birth with coagulopathy and encephalopathy. He is diagnosed with hemochromatosis and is transferred to the Children's Hospital.

*What are etiologies for neonatal liver failure?*

*What is hemochromatosis?*

*What are the natural history, work-up, and management of neonatal liver failure?*

The transplant group puts the patient on the transplant list emergently with the transplant meeting to follow.

*What is the process of putting a patient on the transplant list?  
What is the role of the anesthesiologist?  
How are patients ranked on the pediatric transplant list?  
What should preoperative workup include?  
What should consent include?*

An uncle says he heard he could donate part of his liver and offers to do so. An organ of an older patient becomes available after seven days on the waiting list and the patient is scheduled for liver transplant. He weighs 3kg.

*What are surgical options for liver transplantation in children?*

The patient is induced. The oxygen saturation rapidly declines. Intubation is easy, but the saturation is slow to recover.

*What drugs and techniques should be used for induction?  
What would be possible mechanisms for this desaturation?  
What lines and tubes will be necessary or useful during the procedure?  
What anesthetic maintenance would be suitable?  
Your resident wants to start TXA. Any thoughts?  
What about fenoldopam? Dopamine?  
Will you need a heparin infusion?  
Alprostadil?*

Following your local protocol, the nurse calls for six units PRBCs, six units FFP, six units platelets, six bottles of albumin. The anesthesia technician has set up two buretrols with lactated Ringer's solution and a rapid infuser with saline. There are many episodes of hypotension during induction, during hepatectomy, during reperfusion, and during completion of the transplantation. The platelet count is 80k at the completion of the surgery and the surgeon asks you not to transfuse platelets.

*What fluids and products will you use and do you want available in the OR?  
What are typical times and reasons for intraoperative hypotension?  
What are the classical stages of liver transplantation?  
How do you prepare for reperfusion?  
What are the hematologic goals?*

The surgery is coming to completion and the surgeon asks you to extubate the patient. However, the neonatologist calls you from the NICU and asks you to leave the patient intubated.

*What should be the postoperative disposition for this patient? (NICU vs MSICU, PICU, extubation vs postop ventilation, pain management)*

## **Discussion:**

### **Liver failure and liver transplantation**

#### **Definition of acute liver failure:**

Adult: Severe liver injury in a patient without a previous history of liver disease who develops hepatic encephalopathy within 8 weeks of the initial symptoms.

This definition is not practical in neonates and infants:

Neonatal: Acute liver failure occurring within the first 28 days of birth.

#### **Criteria:**

Hepatic based coagulopathy (PT  $\geq$  15 sec, INR  $\geq$  1.5 not corrected by Vit K in the presence of clinical hepatic encephalopathy or a PT  $\geq$  20sec or INR  $\geq$  2.0 regardless of presence or absence of hepatic encephalopathy)  
(Note: isolated elevated PTT is not due to liver disease)  
Biochemical evidence of acute liver injury  
No known evidence of chronic liver disease

### **Etiologies of liver failure and indications for liver transplant**

Typical indications for liver transplantation in adults:

Fulminant liver failure (acetaminophen, other drugs, indeterminate, viral)  
Complications of cirrhosis  
Hepatocellular carcinoma  
Pulmonary syndromes (hepatopulmonary syndrome, portopulmonary hypertension)  
Polycystic liver disease  
Liver based metabolic disease with systemic complications

Most common indications for liver transplantation in the adult:

Hepatitis C - cirrhosis  
Cholestatic cirrhosis

Alcoholic cirrhosis  
Cryptogenic cirrhosis  
Hepatocellular carcinoma

Typical indications for liver transplantation in pediatrics:

Biliary atresia (>41%)  
Acute liver failure (14.5%)  
Metabolic (14.5%)  
Other cholestatic liver disease  
Cirrhosis  
Tumor

Most common causes of acute liver failure in pediatrics:

1. Indeterminate (50%)
2. Autoimmune
3. Infectious (viral)
4. Toxic (drugs)
5. Metabolic

Typical metabolic disorders treated with liver transplantation in pediatrics:

Crigler-Najjar  
Tyrosinemia  
Organic acidemias  
Urea cycle defects (ornithine transcarbamylase deficiency [OTC deficiency])  
Oxalosis

Etiologies of chronic liver disease in children:

Cholestatic disease  
Biliary atresia  
Progressive familial intrahepatic cholestasis PFIC  
Alagille syndrome  
TPN associated liver disease  
Metabolic liver disease resulting in cirrhosis  
Alpha-1 antitrypsine deficiency  
Tyrosinemia type 1  
Wilson's disease  
Cystic fibrosis  
Glycogen storage disease type 3 or 4  
Chronic hepatitis  
Autoimmune  
Sclerosing cholangitis  
Viral hepatitis  
Others  
Budd Chiari

Liver Tumors in children:

- Hepatoblastoma
- HCC
- Vascular tumors
- Sarcoma
- Hamartoma
- Focal nodular hyperplasia
- Adenoma

### **Causes of neonatal liver failure:**

1. Neonatal hemochromatosis
2. Viral infection (herpes simplex virus most common, herpes family, enterovirus, adenovirus, parvovirus); high dose acyclovir to be started until HSV ruled out
3. Hematologic malignancies (hemophagocytic lymphohistiocytosis HLH: liver transplant contraindicated in HLH)
4. Metabolic (galactosemia: lactose free diet until ruled out, tyrosinemia, hereditary fructose intolerance, ornithine transcarbamylase deficiency, mitochondrial disorders, deficiencies of complex I, III, IV, multiple and mitochondrial DNA depletion syndrome)
5. Others (hypoxic/ischemic, toxic)

**Neonatal hemochromatosis:** rare condition of unknown etiology unrelated to hemochromatosis of the adult

Etiology: Etiology is unknown. May be related to a fetal hepatic insult with a common pathway of iron deposition. Based on association with renal disease, insult may occur around or before 24th week. Prenatal disease process as there is cirrhosis present at birth. Alloimmune mechanism may be involved as there are maternal antibodies against fetal liver antigen resulting in risk to subsequent pregnancies. No paternal risk but high maternal risk (80%) for affected subsequent pregnancy.

Presentation: Decompensated cirrhosis at birth resulting in small liver, normal transaminases, mildly raised bilirubin, markedly reduced albumin, coagulopathy and possibly features of portal hypertension.

Pathophysiology: fetal onset liver injury associated with massive iron deposition (diagnosed by MRI) in liver and extrahepatic tissues including oral mucosa (biopsy), heart and pancreas/endocrine and exocrine glands, but with sparing of the reticulo-endothelial system (spleen); fetal liver insult leads to siderosis (hepatocyte siderosis on biopsy), iron induced oxidant injury causes liver damage (hence antioxidant and chelation therapy)

Diagnosis: prenatal oligohydramnios (intra-uterine hepatorenal syndrome), acute liver failure; two or more of following: family or prenatal history; high serum ferritin; decreased transferrin and increased transferrin saturation; histologic confirmation of iron deposition by lip biopsy or autopsy; extrahepatic (heart, pancreas) iron overload by MRI (also prenatally) in liver and extrahepatic tissue but with sparing of the spleen

Prognosis: poor, 10% survival without transplantation; 50% with liver transplantation

Treatment: desferroxime/deferoxamine (chelates iron: contraindicated in MOF) and N-acetylcysteine (antioxidant cocktail with vitamin E and PGE1, ursodeoxycholic acid, selenium)

Prevention: IVIG antenatal every week after week 18

Indication for liver transplant: INR > 4; (10% die on waiting list, 10% removed due to spontaneous recovery, 80% transplanted)

Other criteria: bilirubin > 235 mmol/l; age < 2 years; WBC > 9000/ml; fibrinogen < 1 g/l; hyperammonemia > 150 mmol/l; worsening lactic acidosis; deterioration within 48 hours of admission; seizures, hepatorenal syndrome

### **Presentation of neonatal liver failure/complications:**

1. Non-specific symptoms: irritability, lethargy, poor feeding, vomiting, failure to thrive, fever; hepatomegaly, splenomegaly, ascites, peripheral edema
2. Encephalopathy (difficult to assess in neonates, excessive crying, poor feeding, sleepiness, lethargy, coma; increased ICP - normoventilation, mannitol, inotropes, N-acetylcysteine; DD intracranial bleed)
3. Infection (54-80% sepsis in adult liver failure; hemodynamic changes similar to SIRS, requiring fluid and possibly inotropes (preferred norepinephrine), if refractory: hydrocortisone)
4. Abnormal liver function tests (increased aminotransferases, increased bilirubin: in viral more than in metabolic diseases), hypoalbuminemia, coagulopathy (factor V and VII levels prognostic, due to short half life they represent synthetic dysfunction well; FVII levels lower than 10-15% of age appropriate predicted level in NH sign of poor prognosis), hypoglycemia (decreased neoglycogenesis, increased insulin), hyperammonemia,

### **Pathophysiology of acute liver failure:**

#### *1. Loss of liver function*

Impaired glucose homeostasis (risk of hypoglycemia from impaired glycogen storage, impaired gluconeogenesis)

Synthetic deficiency (coagulopathy from decreased pro- and anticoagulant proteins, decreased albumin with changed drug binding and oncotic pressure)

Metabolic activity (drug metabolism, encephalopathy)

#### *2. Encephalopathy*

Hyperammonemia, metabolic disturbances, increased cerebral blood flow, increased ICP

Seizures from encephalopathy or hypoglycemia

(Acute management: mannitol, hypertonic saline, moderate hypothermia 32-34)

#### *3. Renal failure*

Prerenal failure

Nephrotoxic medications

Hepatorenal syndrome (vasoconstrictor response to severe arterial underfilling and portal hypertension)

*4. Bacterial infections and sepsis*

Impaired immune and complement function

*5. Cardiovascular changes*

Hypovolemia

Cardiac hyperkinesia with elevated cardiac indices and low systemic vascular resistance

Risk of pulmonary edema, central neurogenic pulmonary edema

Vasoplegia with hypotension, need for alpha-adrenergic agents (norepinephrine)

Adrenal insufficiency (give hydrocortisone)

*6. Pulmonary changes*

Respiratory failure

Atelectasis

Hepatopulmonary syndrome

**Contraindications to liver transplantation:**

10-20% of cases: permanently fixed/dilated pupils; uncontrolled sepsis; severe respiratory failure; uncontrolled intracranial hypertension; uncontrolled multiorgan failure; diseases not cured with liver transplantation (malignant disease, Reye syndrome, mitochondrial respiratory chain disorder with neurologic involvement)

**Outcome of acute liver failure:**

148 infants under 90 days:

60% spontaneous survival

16% liver transplantation

24% death without liver transplantation

**Outcome of liver transplantation (UNOS data):**

Patient (graft) survival 1 and 5 years post transplant

Neonates: not listed separately on UNOS website

Children under 1 year: 89/76 (81/63)%

Children 1-5 years: 85/76 (78/66)%

Children 6-10 years: 90/85 (84/75)%

Adults 50-64 years: 86/70 (82/65)%

**Listing for pediatric liver transplantation:**

Local transplant committee which includes the director of transplant anesthesia discusses indications and contraindications for liver transplant candidates and lists patients with the local Organ Procurement Organization (OPO).

MELD/PELD scores reflect the risk or probability of death within the next 3 months without transplant:

*PELD* score (Pediatric End Stage Liver Disease score) for children under 12 years:  
 $10 \times [-0.687 \times \log e (\text{albumin g/dL}) + 0.480 \times \log e (\text{bilirubin mg/dL}) + 1.857 \times \log e (\text{INR}) + 0.436 (\text{if child} < 1 \text{ year old}) + 0.667 (\text{if growth failure present} < -2 \text{ standard deviations})]$

Range (rounded) 6 - 40

*MELD* score (Model for End Stage Liver Disease) for patients over 12 years of age:  
 $10 \times [0.957 \times \log e (\text{creatinine mg/dL}) + 0.378 \times \log e (\text{bilirubin mg/dL}) + 1.120 \times \log e (\text{INR})] + 6.43$

Range (rounded) 6 - 40

*Exemptions:*

Status 1a: fulminant liver failure

Status 1b: exemption for severely ill pediatric patients (MELD/PELD > 25 plus mechanical ventilation/GI bleed/renal failure/GCS < 10 within 48 hours), no 1b for adults  
Hepatoblastoma: 30 points for 30 days then 1b

Urea cycle defects or organic acidemias: 30 points for 30 days then 1b

Status 1a, 1b: geographic prioritization (local, regional, national)

**Surgical options for neonatal and pediatric liver transplantation:**

living related donation

whole organ (neonatal vs non-neonatal)

split graft

reduced size graft

staged closure (temporary PTFE mesh to temporarily enlarge recipient's abdominal cavity)

piggy-back technique with donor IVC to recipient hepatic vein confluence instead of IVC

clamping for IVC interposition

aorto-hepatic arterial graft instead of end-to-end anastomosis of the hepatic artery

biliary drainage via Roux-en-Y instead of end-to-end anastomosis of bile duct

veno-venous bypass (rare in children)

## **Anesthesia for neonatal liver transplantation**

### **Anesthetic concerns for neonates in general:**

Immaturity of all organ systems

- immature CNS

- immature respiratory system

- immature cardiovascular system

- immature hepatic function

- immature hematologic system

- immature renal function

- immature pharmacokinetics and pharmacodynamics

- immature metabolic function

- immature immune function

- immature endocrine function

Neonatal anatomy:

- neonatal airway

Some implications:

- Concern about neurotoxicity of anesthetics

- Risk for hypoglycemia

- Different therapeutic window and drug dosing

- Risk of postanesthetic apnea

- Intubation

- Difficult line placement

### **Stages of liver transplantation and anesthetic considerations and concerns:**

#### *Preoperative*

Anesthetic history and family history

Assessment of clinical status in particular encephalopathy, cardiorespiratory status, abdomen

Labs: CBC, coags, LFTs, BUN/creat, electrolytes, blood sugar

Imaging studies: CXR, echo, head ultrasound, MRI/CT

#### *Room setup*

Fluids: dextrose 5-10% with electrolytes, Plasmalyte, albumin, PRBCs (washed or less than one week old), fresh thawed plasma, platelets available depending on count, cryo available, not thawed; factor VIIa available

Infusion pumps

Rapid transfusion devices likely less useful in neonates and infants due to iv size limitation

Fluid warmer  
Patient warmer  
Multiple transducers  
Cell saver  
All anesthetic drugs drawn up in neonatal aliquots and dilutions if indicated  
Resuscitation drugs in appropriate dilution and quantity  
Antibiotics and immunosuppressants per surgical protocols

### *Induction*

Sedation if necessary and feasible to allow for preoxygenation  
Ketamine or etomidate vs propofol, rapid sequence (NPO, ascites) with sux vs roc,  
ventilation vs true rapid sequence  
Reasons for desaturation: ascites, mainstem intubation with high diaphragms, poor  
compliance, hepatopulmonary syndrome, aspiration

### *Line placement and monitoring*

standard monitoring  
multiple peripheral ivs (for maintenance, for meds, for volume, backup iv), large bore  
volume lines in neonates may be 22G, volume line preferred above the diaphragm due  
to potential IVC clamping or bleeding  
NIBP plus two invasive arterial monitoring sites (at least one upper extremity)  
central venous access and pressure monitoring  
dual pulse oximetry monitoring (at least one on upper extremity)  
dual temperature monitoring rectal/esophageal  
NIRS in neonates  
BIS in older patients  
TEE  
labs intraop: ABG for oxygenation, ventilation, acid-base-monitoring, electrolytes,  
lactate, blood glucose, hematocrit (goal around 30% for viscosity), platelet count (goal  
above 60k), coagulation studies, TEG

### *Waiting periods*

Due to difficult line placement, we tend to induce early, but there may be a waiting  
period after induction and line placement before incision until the procurement team has  
sent their message, similarly, there may be a waiting period after laparotomy and  
mobilisation of the recipient liver before removal of the liver until the donor organ has  
been optimized on the back table

### *Pre-anhepatic stage (dissection/hepatectomy)*

The preanhepatic stage is the time from incision to hepatectomy. Antibiotics are  
typically administered before incision. The course of this time very much depends on  
the underlying liver disease. Patients in liver failure will be coagulopathic, patients with

cirrhosis will have bleeding from collaterals, patients with metabolic or oncologic diseases may have normal coagulation, patients with previous surgeries (Kasai procedure for biliary atresia) will have adhesions with potential bleeding; blood transfusions and calcium administration are typically required during this stage in neonates undergoing liver transplantation for acute liver failure, glucose administration may be necessary in liver failure, dopamine may be started in renal dose for diuresis and anticipating increased requirements during reperfusion; there is often pronounced hemodynamic instability related to surgical manipulation of the venous return

### *Anhepatic stage*

During the anhepatic stage, venous return is surgically impaired; depending on the surgical technique, the entire IVC blood flow may be interrupted or only the hepatic venous return; veno-venous bypass is not feasible in neonates; volume administration must be judicious to avoid overfilling after reperfusion; increase in dopamine rate may be initiated; blood sugar must be checked to avoid hypoglycemia during the anhepatic phase; ABG and electrolytes should be checked to correct hypocalcemia and acidosis or address hyperkalemia prior to reperfusion; drop in patient temperature may be noted during this time; immunosuppressant and steroids are often administered during this time

### *Reperfusion*

Prior to reperfusion, a blood flush may be used to wash out cold, acidotic, hyperkalemic preservative fluid from the donor organ; in neonates this may constitute a large portion of their circulating blood volume and should be accompanied by blood transfusion, calcium administration and increased dopamine infusion; even in spite of the blood flush, reperfusion may be followed by hyperkalemia, profound acidosis, acute hypothermia, air or particulate embolisation, acute cardiac failure and arrhythmias, and hypovolemia, all resulting in profound hypotension and possibly cardiac arrest; hyperkalemia, acidosis and hypovolemia must be treated aggressively and use of higher doses of dopamine or small bolus doses or continuous infusion of epinephrine may become necessary

### *Post-anhepatic*

During the post-anhepatic phase following reperfusion, the hepatic artery anastomosis and the biliary drainage are completed, the abdomen is closed and typically ultrasound studies are performed at various stages to monitor vascular patency; due to the high concern regarding hepatic artery thrombosis, the surgeon may ask for heparin or alprostadil drips to be started; there may be less but continuing blood loss and blood product management should be cautious and in discussion with the surgeon; hematocrit not over 30 and platelet count down to 60 are our local surgeon's preference; following the immunosuppressive steroid dose, blood transfusions and liver reperfusion, the blood sugar may be very high and require intervention; liver function may be noticeable with decreasing lactate levels, increasing alkalosis (from citrate metabolism) and improving clotting studies without further plasma transfusion

### *Postoperative disposition*

All patients following liver transplantation will be recovered in an ICU. Neonates may be coming from the NICU, but the surgical ICU may be more used to management protocols following liver transplantation; generally following liver transplantation, extubation should be considered unless contraindications to extubation exist; neonates may be at increased risk for postoperative apnea and the need for reintubation due to their immaturity and their response to opioid analgesics, and postoperative ventilation may be indicated; postoperative analgesia typically is by intravenous opioids.

### *Return to OR*

Hepatic artery thrombosis is a high risk in pediatric liver transplant and requires urgent re-exploration for possible thrombectomy; patients may also return to the OR for management of bleeding, completion of biliary drainage or abdominal closure.

## **Complications**

Intraop and postop complications including anesthetic neurotoxicity, hypoglycemia, metabolic stroke (with certain metabolic disorders such as aromatic acidemias), intraventricular hemorrhage or ischemia; hypotension (multiple etiologies including bleeding, impaired venous return from surgical retraction, clamping, abdominal compartment syndrome, pulmonary hypertension, ventricular insufficiency, peripheral vascular dilation, hypocalcemia), hypothermia, hyperkalemia (from reperfusion flush, transfusion and acidosis), acute arrhythmias from cold, electrolyte (potassium, calcium, magnesium) or acidosis related changes; intractable bleeding (surgical, coagulopathy, hypothermia); surgical and postoperative complications include bleeding; hepatic artery thrombosis, portal vein thrombosis, biliary leak; rejection, infection; abdominal compartment syndrome; renal failure.

### References:

Devictor D et al. Acute liver failure in neonates, infants and children. *Expert Rev Gastroenterol Hepatol* 2011;5:717

Hammer GB, Krane EJ. Anaesthesia for liver transplantation in children. *Paediatr Anaesth* 2001; 11: 3 - 18

Shanmugam NP, Bansal S, Greenough A, Verma A, Dhawan A. Neonatal liver failure: aetiologies and management - state of the art. *Eur J Pediatr* 2011; 170: 573 - 581

Sundaram SS, Alonso EM, Narkewicz MR, Zhang S, Squires RH, and the Pediatric Acute Liver Failure Study Group. Characterization and outcomes of young infants with acute liver failure. *J Pediatr* 2011; 159: 813 - 818

Yudkowitz FS, Chietero M. Anesthetic issues in pediatric liver transplantation. *Pediatr Transplantation* 2005;9:666